Viewing Study NCT02939820

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:07 AM
Ignite Modification Date: 2026-02-26 @ 2:22 AM
Study NCT ID: NCT02939820
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2024-05-20
First Post: 2016-10-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Sponsor: Alnylam Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None TTR-mediated Amyloidosis View
None Amyloidosis, Hereditary View
None Amyloid Neuropathies, Familial View
None Familial Amyloid Polyneuropathies View
None Amyloid Neuropathies View
None Amyloidosis, Hereditary, Transthyretin-Related View
Keywords:

Keywords

Keyword Brief Keyword Text View
None RNAi therapeutic View
None FAP View
None Familial Amyloid Polyneuropathies View
None TTR View
None Transthyretin View
None Amyloidosis View